Joint Formulary & PAD

Prucalopride - Constipation

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important
Only after a trial of at least 2 other classes of laxative at the highest recommended, tolerated doses. Consider stopping after 4 weeks if not effective.

PAD Profile

ChemicalSubstance :
Prucalopride
Indication :
Constipation
Group Name :
Keywords :
NICE
Brand Names Include :
Resolor
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (2)

The Surrey Heartlands APC have adopted the CKS principles for the management of constipation in adults.

Management | Constipation | CKS | NICE

The CKS guidance covers the management of constipation in adults (including pregnant women and those who are breastfeeding), for short-duration and chronic constipation, and faecal loading and/or impaction.

Refer to the formulary for Traffic Light status / place in therapy of locally agreed treatment options.

Treatment with prucalopride (October 2019 review)

1. Patient should have been treated with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, and these treatments have failed to provide adequate relief and invasive treatment for constipation is being considered.

2. If treatment is not effective after 4 weeks then consider stopping treatment.

Other Indications

Below are listed other indications that Prucalopride is used to treat.